Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
Researchers at Stanford have identified the use of the drug verteporfin to treat or reduce the risk of developing ibrosis after ocular procedures or ocular injury. Of interest is corneal injury, for example after refractive surgery or crosslinking, e.g.
Researchers at Stanford have developed innovative Verteporfin conjugates that considerably enhance the solubility and therapeutic potential of Verteporfin.